AstraZeneca Trust for Defined Benefit Pension Plans

Public filings show the trust holds title to commercial and residential properties through a series of LLCs, including sites in New York, Delaware, and Michigan. This corporate structure strongly suggests direct ownership and asset management rather than an entirely passive REIT strategy, though the trust may contract third-party property managers for day-to-day operations.

As a US-based trust for defined benefit plans, it operates with a fiduciary duty to plan participants independent of AstraZeneca PLC's corporate balance sheet. The plan sponsor is AstraZeneca Pharmaceuticals LP, a US subsidiary, placing the trust under ERISA regulations that require exclusive benefit to members, even as the parent company ultimately backs the funding obligations.

The strategy is liability-driven, as is standard for a closed or frozen corporate defined benefit plan, meaning the portfolio must generate returns sufficient to cover fixed monthly payouts to retirees over multi-decade horizons. The direct real estate component provides long-duration, inflation-sensitive cash flows that naturally match these obligations.

The trust's publicly visible footprint centers on direct real estate rather than well-known venture or buyout fund commitments. Standard corporate pension practice would include public equities and fixed income, but specific LP commitments to third-party private funds are not a matter of readily available public record for this entity.

Like many large pharmaceutical corporate plans, AstraZeneca likely froze or closed its US defined benefit plan to new entrants years ago, shifting to defined contribution 401(k) structures, though the specific freeze date is not explicitly confirmed in the available Altss research record on the trust.